204 related articles for article (PubMed ID: 37337460)
1. Genomic profiling, prognosis, and potential interventional targets in young and old patients with cholangiocarcinoma.
Wang J; Shi Y; Chen J; Liu J; Zhao X; Pang J; Sun X; Tian Y; Ou Q; Xia F; Chen Y
Cancer Biol Ther; 2023 Dec; 24(1):2223375. PubMed ID: 37337460
[TBL] [Abstract][Full Text] [Related]
2. Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.
Boerner T; Drill E; Pak LM; Nguyen B; Sigel CS; Doussot A; Shin P; Goldman DA; Gonen M; Allen PJ; Balachandran VP; Cercek A; Harding J; Solit DB; Schultz N; Kundra R; Walch H; D'Angelica MI; DeMatteo RP; Drebin J; Kemeny NE; Kingham TP; Simpson AL; Hechtman JF; Vakiani E; Lowery MA; Ijzermans JNM; Buettner S; Koerkamp BG; Doukas M; Chandwani R; Jarnagin WR
Hepatology; 2021 Sep; 74(3):1429-1444. PubMed ID: 33765338
[TBL] [Abstract][Full Text] [Related]
3. Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets.
Zhu AX; Borger DR; Kim Y; Cosgrove D; Ejaz A; Alexandrescu S; Groeschl RT; Deshpande V; Lindberg JM; Ferrone C; Sempoux C; Yau T; Poon R; Popescu I; Bauer TW; Gamblin TC; Gigot JF; Anders RA; Pawlik TM
Ann Surg Oncol; 2014 Nov; 21(12):3827-34. PubMed ID: 24889489
[TBL] [Abstract][Full Text] [Related]
4. Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures.
Mody K; Jain P; El-Refai SM; Azad NS; Zabransky DJ; Baretti M; Shroff RT; Kelley RK; El-Khouiery AB; Hockenberry AJ; Lau D; Lesinski GB; Yarchoan M
JCO Precis Oncol; 2022 Jun; 6():e2100510. PubMed ID: 35675577
[TBL] [Abstract][Full Text] [Related]
5. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.
Andersen JB; Spee B; Blechacz BR; Avital I; Komuta M; Barbour A; Conner EA; Gillen MC; Roskams T; Roberts LR; Factor VM; Thorgeirsson SS
Gastroenterology; 2012 Apr; 142(4):1021-1031.e15. PubMed ID: 22178589
[TBL] [Abstract][Full Text] [Related]
6. Exploring the Clinical Use of Molecular Profiling of Intrahepatic Cholangiocarcinoma in a Comprehensive Multidisciplinary Clinic.
Purchla J; Ghabi EM; Burns WR; Lafaro KJ; Burkhart RA; Cameron JL; Yarchoan M; Shubert CR; Baretti M; He J
J Am Coll Surg; 2024 Apr; 238(4):532-540. PubMed ID: 38189646
[TBL] [Abstract][Full Text] [Related]
7. KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients.
Xu RF; Sun JP; Zhang SR; Zhu GS; Li LB; Liao YL; Xie JM; Liao WJ
Biomed Pharmacother; 2011 Feb; 65(1):22-6. PubMed ID: 21051183
[TBL] [Abstract][Full Text] [Related]
8. Practical considerations in screening for genetic alterations in cholangiocarcinoma.
Bekaii-Saab TS; Bridgewater J; Normanno N
Ann Oncol; 2021 Sep; 32(9):1111-1126. PubMed ID: 33932504
[TBL] [Abstract][Full Text] [Related]
9. Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma.
Kongpetch S; Jusakul A; Lim JQ; Ng CCY; Chan JY; Rajasegaran V; Lim TH; Lim KH; Choo SP; Dima S; Popescu I; Duda DG; Kukongviriyapan V; Khuntikeo N; Pairojkul C; Rozen SG; Tan P; Teh BT
JCO Glob Oncol; 2020 Apr; 6():628-638. PubMed ID: 32315234
[TBL] [Abstract][Full Text] [Related]
10. Mutational spectrum and precision oncology for biliary tract carcinoma.
Lin J; Cao Y; Yang X; Li G; Shi Y; Wang D; Long J; Song Y; Mao J; Xie F; Bai Y; Zhang L; Yang X; Wan X; Wang A; Guan M; Zhao L; Hu K; Pan J; Huo L; Lu X; Mao Y; Sang X; Zhang H; Wang K; Wang X; Zhao H
Theranostics; 2021; 11(10):4585-4598. PubMed ID: 33754015
[No Abstract] [Full Text] [Related]
11. Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers.
Tang TY; Nichetti F; Kaplan B; Lonardi S; Pietrantonio F; Salvatore L; Vivaldi C; Rimassa L; de Braud F; Rizzato MD; Pavlick D; Chu R; Danner De Armas A; Sharaf R; Sokol E; Rodon Ahnert J; Ross JS; Javle M; Niger M
Clin Cancer Res; 2023 Dec; 29(23):4853-4862. PubMed ID: 37773629
[TBL] [Abstract][Full Text] [Related]
12. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.
Ross JS; Wang K; Gay L; Al-Rohil R; Rand JV; Jones DM; Lee HJ; Sheehan CE; Otto GA; Palmer G; Yelensky R; Lipson D; Morosini D; Hawryluk M; Catenacci DV; Miller VA; Churi C; Ali S; Stephens PJ
Oncologist; 2014 Mar; 19(3):235-42. PubMed ID: 24563076
[TBL] [Abstract][Full Text] [Related]
13. ESMO Scale for Clinical Actionability of Molecular Targets Driving Targeted Treatment in Patients with Cholangiocarcinoma.
Verdaguer H; Saurí T; Acosta DA; Guardiola M; Sierra A; Hernando J; Nuciforo P; Miquel JM; Molero C; Peiró S; Serra-Camprubí Q; Villacampa G; Aguilar S; Vivancos A; Tabernero J; Dienstmann R; Macarulla T
Clin Cancer Res; 2022 Apr; 28(8):1662-1671. PubMed ID: 35042699
[TBL] [Abstract][Full Text] [Related]
14. Role of molecular genetics in the clinical management of cholangiocarcinoma.
Normanno N; Martinelli E; Melisi D; Pinto C; Rimassa L; Santini D; Scarpa A
ESMO Open; 2022 Jun; 7(3):100505. PubMed ID: 35696744
[TBL] [Abstract][Full Text] [Related]
15.
Angerilli V; Fornaro L; Pepe F; Rossi SM; Perrone G; Malapelle U; Fassan M
Pathologica; 2023 Apr; 115(2):71-82. PubMed ID: 37017301
[TBL] [Abstract][Full Text] [Related]
16. Molecular Profiling and Targeted Therapy in Cholangiocarcinoma: An Observational, Retrospective Multicenter Study.
Garcia-Pardo M; Ortega L; Fernández-Aceñero MJ; García Alfonso P; Martín M; Muñoz AJ
J Gastrointest Cancer; 2021 Jun; 52(2):814-818. PubMed ID: 33683644
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitor-related molecular markers predict prognosis in extrahepatic cholangiocarcinoma.
Jin B; Wang Y; Zhang B; Xu H; Lu X; Sang X; Wang W; Mao Y; Chen P; Wang S; Qian Z; Wang Y; Du S
Cancer Med; 2023 Oct; 12(20):20470-20481. PubMed ID: 37814942
[TBL] [Abstract][Full Text] [Related]
18. The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.
Chong DQ; Zhu AX
Oncotarget; 2016 Jul; 7(29):46750-46767. PubMed ID: 27102149
[TBL] [Abstract][Full Text] [Related]
19. Correlation between KRAS gene mutations and linicopathological features of patients with intrahepatic cholangiocarcinoma.
Wang J; Xu MX; Wang LQ; Li HY; Wang ZL; Li LJ
J Biol Regul Homeost Agents; 2019; 33(5):1551-1557. PubMed ID: 31635679
[No Abstract] [Full Text] [Related]
20. FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations.
Uson Junior PLS; DeLeon TT; Bogenberger JM; Pai RK; Kosiorek HE; Yin J; Ahn DH; Sonbol MB; Bekaii-Saab T; Mansfield AS; Buetow K; Gores GJ; Smoot R; Vasmatzis G; Kipp BR; Mahipal A; Baker AT; Babiker H; Barro O; Dumbauld C; Zhou Y; Aslam FN; Barrett M; Jacobs B; Meurice N; Arora M; Petit J; Elliott N; Nagalo B; Salomao MA; Borad MJ
Dig Dis Sci; 2022 Aug; 67(8):3797-3805. PubMed ID: 34773565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
